Article Information
- Received November 21, 2011
- Revision received February 14, 2012
- Accepted February 19, 2012
- First published April 11, 2012.
- Version of record published April 11, 2012.
Author Information
Author contributions
Author contributions: L.T.H. and C.E.B. designed research; L.T.H. and M.W. performed research; L.T.H., M.W., M.G., and C.E.B. analyzed data; C.E.B. wrote the paper.
Disclosures
- Received November 21, 2011.
- Revision received February 14, 2012.
- Accepted February 19, 2012.
This work was supported by National Institutes of Health Grant NS050414 (C.E.B.), by The SMA Foundation (C.E.B.) with additional support from The Ohio State University Neuroscience Center Core Grant P30 NS045758, by National Research Service Award Postdoctoral Fellowship 5F32EY019434-03 (M.W.), and by National Institutes of Health Grant MH092257 (M.G.). We thank The Ohio State University fish facility staff for fish care and Dr. Brunhilde Wirth for the PLS3 antibody, Dr. Livio Pellizzoni for the gemin 2 antibody, and Dr. Glenn Morris for the SMN, gemin 5, and profillin 2 antibodies. The SV2 monoclonal antibody developed by K. M. Buckley was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Development and maintained by the Department of Biology, University of Iowa (Iowa City, IA).
The authors declare no competing financial interests.
- Correspondence should be addressed to Christine E. Beattie, 190 Rightmire Hall, 1060 Carmack Road, Columbus, OH 43210. beattie.24{at}osu.edu
Online Impact